Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 December 2012Website:
http://www.biorestorative.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
BRTX Latest News
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Executive Officer Francisco Silva – Vice President-Research and Development Conference Call Participants Jonathan Aschoff – ROTH Capital Michael Okunewitch – Maxim Group Elemer Piros – Rodman Operator Greetings. Welcome to the BioRestorative Third Quarter 2024 Results and New Additional Preliminary BRTX-100 Phase 2 Study Data Review Conference Call.
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Executive Officer, Lance Alstodt, will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City.
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.77 per share a year ago.
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has been named Section Editor of the newly launched Regenerative Medicine section of the Journal of Translational Medicine.
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders –
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.53 per share a year ago.
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) held its Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. The call featured company representatives including Stephen Kilmer, Lance Alstodt, Robert Kristal, and Francisco Silva, along with conference call participants Michael Okunewitch and Jonathan Aschoff. Good afternoon, everyone, and welcome to the BioRestorative Therapies Q1 Business Update Conference Call. Participants are currently in a listen-only mode, and questions will be addressed following the presentation.
What type of business is BioRestorative Therapies?
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.
What sector is BioRestorative Therapies in?
BioRestorative Therapies is in the Healthcare sector
What industry is BioRestorative Therapies in?
BioRestorative Therapies is in the Biotechnology industry
What country is BioRestorative Therapies from?
BioRestorative Therapies is headquartered in United States
When did BioRestorative Therapies go public?
BioRestorative Therapies initial public offering (IPO) was on 05 December 2012
What is BioRestorative Therapies website?
https://www.biorestorative.com
Is BioRestorative Therapies in the S&P 500?
No, BioRestorative Therapies is not included in the S&P 500 index
Is BioRestorative Therapies in the NASDAQ 100?
No, BioRestorative Therapies is not included in the NASDAQ 100 index
Is BioRestorative Therapies in the Dow Jones?
No, BioRestorative Therapies is not included in the Dow Jones index
When was BioRestorative Therapies the previous earnings report?
No data
When does BioRestorative Therapies earnings report?
Next earnings report date is not announced yet